|
|
Blood, 15 August 2005, Vol. 106, No. 4, pp. 1495-1500.
Prepublished online as a Blood First Edition Paper on May 5, 2005; DOI 10.1182/blood-2004-11-4557.
Previous Article | Next Article 
Submitted December 1, 2004
Accepted April 15, 2005
Prospective evaluation of two acute graft-versus-host (GVHD) grading systems: A joint Societe Francaise de Greffe de Moelle et Therapie Cellulaire (SFGM-TC), Dana Farber Cancer Institute (DFCI) and International Bone Marrow Transplant Registry (IBMTR) prospective study
Jean-Yves Cahn*, John P Klein, Stephanie J Lee, Noel Milpied, Didier Blaise, Joseph H Antin, Veronique Leblond, Norbert Ifrah, Jean- Pierre Jouet, Fausto Loberiza, Olle Ringden, A J Barrett, Mary M Horowitz, and Gerard Socie
Hematology Department, Centre Hospitalo-Universitaire, Grenoble, France
International Bone Marrow Transplant Registry, Medical College of Wisconsin, Milwaukee, WI, USA
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
Hematology Department, Centre Hospitalo-Universitaire, Nantes, France
Hematology Department, Institut Paoli-Calmettes, Marseille, France
Hematology Department, Hopital La Pitie Salpetriere, Paris, France
Hematology Department, Centre Hospitalo-Universitaire Angers, Angers, France
Hematology Department, Centre Hospitalo-Universitaire Lille, Lille, France
Huddinge University Hospital, Stockholm, Sweden
National Institute of Health, Bethesda, MD, USA
Hopital Saint-Louis, Paris, France
* Corresponding author; email: JYCahn{at}chu-grenoble.fr.
The most commonly used grading system for acute graft-versus-host disease (aGVHD) was introduced thirty years ago by Glucksberg; a revised system was developed by the International Bone Marrow Transplant Registry (IBMTR) in 1997. To prospectively compare the two classifications and to evaluate the effect of duration and severity of aGVHD on survival, we conducted a multicenter study of 607 patients receiving T cell replete allografts, scored weekly for aGVHD in 18 transplant centers. Sixty-nine percent of donors were HLA-identical siblings and 28%, unrelated donors. The conditioning regimen included total body irradiation in 442 (73%) patients. The two classifications performed similarly in explaining variability in survival by aGVHD grade though the Glucksberg classification predicted early survival better. There was less physician bias or error in assigning grades with the IBMTR scoring system. With either system, only maximum observed grade had prognostic significance for survival; neither time of onset nor progression from an initially lower grade of aGVHD was associated with survival once maximum grade was considered. Regardless of scoring system, aGVHD severity accounted for only a small percentage of observed variation in survival. Validity of these results in populations receiving peripheral blood transplants or non-myeloablative conditioning regimens remains to be tested.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
S. Paczesny, T. M. Braun, J. E. Levine, J. Hogan, J. Crawford, B. Coffing, S. Olsen, S. W. Choi, H. Wang, V. Faca, et al.
Elafin Is a Biomarker of Graft-Versus-Host Disease of the Skin
Science Translational Medicine,
January 6, 2010;
2(13):
13ra2 - 13ra2.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Pavletic
aGVHDAI: escape from the silo
Blood,
July 15, 2006;
108(2):
412 - 413.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. M. Leisenring, P. J. Martin, E. W. Petersdorf, A. E. Regan, N. Aboulhosn, J. M. Stern, S. N. Aker, R. C. Salazar, and G. B. McDonald
An acute graft-versus-host disease activity index to predict survival after hematopoietic cell transplantation with myeloablative conditioning regimens
Blood,
July 15, 2006;
108(2):
749 - 755.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|